Transient receptor potential melastatin 3: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (Text replacement - "|first2=" to " | first2 = ")
m (Text replacement - "|first5=" to " | first5 = ")
Line 8: Line 8:
   
   
==Notable studies==
==Notable studies==
*2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment<ref name="Cabanas2021">{{Cite journal|title=Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment | date = 2021|url=https://www.frontiersin.org/articles/10.3389/fimmu.2021.687806|journal=Frontiers in Immunology|volume=12|issue= | pages = 687806|last=Cabanas | first = Helene|author-link=Hélène Cabanas | last2 = Muraki | first2 = Katsuhiko|author-link2 = | last3 = Eaton-Fitch | first3 = Natalie|author-link3=Natalie Eaton-Fitch | last4 = Staines | first4=Donald Ross | authorlink4 = Donald Staines|last5 = Marshall-Gradisnik|first5=Sonya | authorlink5 = Sonya Marshall-Gradisnik|doi=10.3389/fimmu.2021.687806|pmc=PMC8313851|pmid=34326841|access-date=|issn=1664-3224|quote=|via=}}</ref> - [https://www.frontiersin.org/articles/10.3389/fimmu.2021.687806/full (Full text)]
*2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment<ref name="Cabanas2021">{{Cite journal|title=Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment | date = 2021|url=https://www.frontiersin.org/articles/10.3389/fimmu.2021.687806|journal=Frontiers in Immunology|volume=12|issue= | pages = 687806|last=Cabanas | first = Helene|author-link=Hélène Cabanas | last2 = Muraki | first2 = Katsuhiko|author-link2 = | last3 = Eaton-Fitch | first3 = Natalie|author-link3=Natalie Eaton-Fitch | last4 = Staines | first4=Donald Ross | authorlink4 = Donald Staines|last5 = Marshall-Gradisnik | first5 = Sonya | authorlink5 = Sonya Marshall-Gradisnik|doi=10.3389/fimmu.2021.687806|pmc=PMC8313851|pmid=34326841|access-date=|issn=1664-3224|quote=|via=}}</ref> - [https://www.frontiersin.org/articles/10.3389/fimmu.2021.687806/full (Full text)]


*2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients<ref name="Cabanas2019">{{Cite journal|last=Cabanas | first = H.|author-link=Hélène Cabanas | last2 = Muraki | first2 = K.|author-link2 = | last3 = Balinas | first3=C.|author-link3=Cassandra Balinas | last4 = Eaton-Fitch | first4 = N. | authorlink4 = Natalie Eaton-Fitch|last5 = Staines | first5= D.  | authorlink5 = Donald Staines | last6 = Marshall-Gradisnik | first6 = S. | authorlink6 = Sonya Marshall-Gradisnik | date = Dec 2019|title=Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients|url=https://molmed.biomedcentral.com/articles/10.1186/s10020-019-0083-4|journal=Molecular Medicine|language=en|volume=25|issue=14|pages=|doi=10.1186/s10020-019-0083-4|issn=1076-1551|quote=|via=|pmc=|pmid=|access-date=}}</ref> - [https://link.springer.com/article/10.1186/s10020-019-0083-4 (Full text)]
*2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients<ref name="Cabanas2019">{{Cite journal|last=Cabanas | first = H.|author-link=Hélène Cabanas | last2 = Muraki | first2 = K.|author-link2 = | last3 = Balinas | first3=C.|author-link3=Cassandra Balinas | last4 = Eaton-Fitch | first4 = N. | authorlink4 = Natalie Eaton-Fitch|last5 = Staines | first5= D.  | authorlink5 = Donald Staines | last6 = Marshall-Gradisnik | first6 = S. | authorlink6 = Sonya Marshall-Gradisnik | date = Dec 2019|title=Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients|url=https://molmed.biomedcentral.com/articles/10.1186/s10020-019-0083-4|journal=Molecular Medicine|language=en|volume=25|issue=14|pages=|doi=10.1186/s10020-019-0083-4|issn=1076-1551|quote=|via=|pmc=|pmid=|access-date=}}</ref> - [https://link.springer.com/article/10.1186/s10020-019-0083-4 (Full text)]
Line 18: Line 18:
*2016, Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients<ref name="Marshall2016">{{Cite journal|last=Marshall-Gradisnik | first = S.M.|author-link=Sonya Marshall-Gradisnik | last2 = Chacko | first2 = A. | authorlink2 = A Chacko | last3 = Johnston | first3=S.|author-link3=Samantha Johnston | last4 = Smith | first4 = P. | authorlink4 = Peter Smith|last5 = Nilius | first5=B. | authorlink5 = B Nilius | last6 = Staines | first6= D.R. | authorlink6 = Donald Staines | date = 2016-01-01|title=Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients|url=https://doi.org/10.4137/III.S37042|journal=Immunology and Immunogenetics Insights|language=en|volume=8|issue=|pages=III.S37042|doi=10.4137/III.S37042|issn=1178-6345|quote=|via=}}</ref> - [https://journals.sagepub.com/doi/full/10.4137/III.S37042 (Full text)]
*2016, Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients<ref name="Marshall2016">{{Cite journal|last=Marshall-Gradisnik | first = S.M.|author-link=Sonya Marshall-Gradisnik | last2 = Chacko | first2 = A. | authorlink2 = A Chacko | last3 = Johnston | first3=S.|author-link3=Samantha Johnston | last4 = Smith | first4 = P. | authorlink4 = Peter Smith|last5 = Nilius | first5=B. | authorlink5 = B Nilius | last6 = Staines | first6= D.R. | authorlink6 = Donald Staines | date = 2016-01-01|title=Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients|url=https://doi.org/10.4137/III.S37042|journal=Immunology and Immunogenetics Insights|language=en|volume=8|issue=|pages=III.S37042|doi=10.4137/III.S37042|issn=1178-6345|quote=|via=}}</ref> - [https://journals.sagepub.com/doi/full/10.4137/III.S37042 (Full text)]
*2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients<ref name="Huth2016">{{Cite journal|last=Huth | first = Teilah Kathryn|author-link=Teilah Huth | last2 = Staines | first2=Donald | authorlink2 = Donald Staines | last3 = Marshall-Gradisnik | first3 = Sonya | author-link3=Sonya Marshall-Gradisnik | date = 2016-04-21|title=ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients|url=https://doi.org/10.1186/s12967-016-0859-z|journal=Journal of Translational Medicine|volume=14|issue=1 | pages = 97|doi=10.1186/s12967-016-0859-z|issn=1479-5876|pmc=4839077|pmid=27098723|quote=|via=}}</ref> - [http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0859-z (Full text)
*2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients<ref name="Huth2016">{{Cite journal|last=Huth | first = Teilah Kathryn|author-link=Teilah Huth | last2 = Staines | first2=Donald | authorlink2 = Donald Staines | last3 = Marshall-Gradisnik | first3 = Sonya | author-link3=Sonya Marshall-Gradisnik | date = 2016-04-21|title=ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients|url=https://doi.org/10.1186/s12967-016-0859-z|journal=Journal of Translational Medicine|volume=14|issue=1 | pages = 97|doi=10.1186/s12967-016-0859-z|issn=1479-5876|pmc=4839077|pmid=27098723|quote=|via=}}</ref> - [http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0859-z (Full text)
*2016, Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients<ref name="Nguyen2016">{{Cite journal|last=Nguyen | first = T.|author-link=Thao Nguyen | last2 = Staines | first2= D.  | authorlink2 = Donald Staines | last3 = Nilius | first3=B.|author-link3=B Nilius | last4 = Smith | first4 = P. | authorlink4 = Peter Smith|last5 = Marshall-Gradisnik|first5=S. | authorlink5 = Sonya Marshall-Gradisnik | date = 2016-05-31|title=Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients|url=https://doi.org/10.1186/s40659-016-0087-2|journal=Biological Research|volume=49|issue=1|pages=27|doi=10.1186/s40659-016-0087-2|issn=0717-6287|pmc=4888729|pmid=27245705|quote=|via=}}</ref> - [https://biolres.biomedcentral.com/articles/10.1186/s40659-016-0087-2 (Full text)]
*2016, Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients<ref name="Nguyen2016">{{Cite journal|last=Nguyen | first = T.|author-link=Thao Nguyen | last2 = Staines | first2= D.  | authorlink2 = Donald Staines | last3 = Nilius | first3=B.|author-link3=B Nilius | last4 = Smith | first4 = P. | authorlink4 = Peter Smith|last5 = Marshall-Gradisnik | first5 = S. | authorlink5 = Sonya Marshall-Gradisnik | date = 2016-05-31|title=Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients|url=https://doi.org/10.1186/s40659-016-0087-2|journal=Biological Research|volume=49|issue=1|pages=27|doi=10.1186/s40659-016-0087-2|issn=0717-6287|pmc=4888729|pmid=27245705|quote=|via=}}</ref> - [https://biolres.biomedcentral.com/articles/10.1186/s40659-016-0087-2 (Full text)]


*2015, Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients]<ref name="Marshall2015">{{Cite journal|last=Marshall-Gradisnik | first = Sonya M.|author-link=Sonya Marshall-Gradisnik | last2 = Smith | first2 = Peter | authorlink2 = Peter Smith | last3 = Brenu | first3 = Ekua W.|author-link3=Ekua Brenu | last4 = Nilius | first4=Bernd | author-link4=Bernd Nilius|last5 = Ramos | first5=Sandra B. | authorlink5 = Sandra Ramos | last6 = Staines | first6=Donald R. | date=2015-01-01|title=Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients|url=https://doi.org/10.4137/III.S25147|journal=Immunology and Immunogenetics Insights|language=en|volume=7|issue=|pages=III.S25147|doi=10.4137/III.S25147|issn=1178-6345|quote=|via=}}</ref> - [https://journals.sagepub.com/doi/full/10.4137/III.S25147 (Abstract)] - small study - 115 people with ME/CFS
*2015, Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients]<ref name="Marshall2015">{{Cite journal|last=Marshall-Gradisnik | first = Sonya M.|author-link=Sonya Marshall-Gradisnik | last2 = Smith | first2 = Peter | authorlink2 = Peter Smith | last3 = Brenu | first3 = Ekua W.|author-link3=Ekua Brenu | last4 = Nilius | first4=Bernd | author-link4=Bernd Nilius|last5 = Ramos | first5=Sandra B. | authorlink5 = Sandra Ramos | last6 = Staines | first6=Donald R. | date=2015-01-01|title=Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients|url=https://doi.org/10.4137/III.S25147|journal=Immunology and Immunogenetics Insights|language=en|volume=7|issue=|pages=III.S25147|doi=10.4137/III.S25147|issn=1178-6345|quote=|via=}}</ref> - [https://journals.sagepub.com/doi/full/10.4137/III.S25147 (Abstract)] - small study - 115 people with ME/CFS
*2015, Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis<ref name="NKcells-2015">{{Cite journal|last=Huth | first = T.K. |author-link=Teilah Huth | last2 = Brenu | first2 = E.W. | authorlink2 = Ekua Brenu | last3 = Ramos | first3=S.|author-link3=Sandra Ramos | last4 = Nguyen | first4=T. | authorlink4 = Thao Nguyen|last5 = Broadley|first5=S. | authorlink5 = Simon Broadley | last6 = Staines | first6= D.  | authorlink6 = Donald Staines | last7 = Marshall‐Gradisnik | first7 = S. | authorlink7 = Sonya Marshall-Gradisnik | date = 2016 | title=Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis|url=https://onlinelibrary.wiley.com/doi/abs/10.1111/sji.12388|journal=Scandinavian Journal of Immunology|language=en|volume=83|issue=1|pages=44–51|doi=10.1111/sji.12388|issn=1365-3083|quote=|via=}}</ref> - [https://onlinelibrary.wiley.com/doi/10.1111/sji.12388/abstract (Abstract)
*2015, Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis<ref name="NKcells-2015">{{Cite journal|last=Huth | first = T.K. |author-link=Teilah Huth | last2 = Brenu | first2 = E.W. | authorlink2 = Ekua Brenu | last3 = Ramos | first3=S.|author-link3=Sandra Ramos | last4 = Nguyen | first4=T. | authorlink4 = Thao Nguyen|last5 = Broadley | first5 = S. | authorlink5 = Simon Broadley | last6 = Staines | first6= D.  | authorlink6 = Donald Staines | last7 = Marshall‐Gradisnik | first7 = S. | authorlink7 = Sonya Marshall-Gradisnik | date = 2016 | title=Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis|url=https://onlinelibrary.wiley.com/doi/abs/10.1111/sji.12388|journal=Scandinavian Journal of Immunology|language=en|volume=83|issue=1|pages=44–51|doi=10.1111/sji.12388|issn=1365-3083|quote=|via=}}</ref> - [https://onlinelibrary.wiley.com/doi/10.1111/sji.12388/abstract (Abstract)


==News and blogs==
==News and blogs==

Revision as of 01:04, December 1, 2022

Transient Receptor Potential Melastatin 3 or TRPM3 is an ion channel, and TRPM3 function is a potential biomarker for ME/CFS.[1] TRPM3 may also be used to refer to the gene for TRPM3.

Function[edit | edit source]

ME/CFS[edit | edit source]

Notable studies[edit | edit source]

  • 2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment[2] - (Full text)
  • 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[1] - (Full text)
  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients[3] - (Abstract)
  • 2016, Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[6] - (Full text)
  • 2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[7] - [http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0859-z (Full text)
  • 2016, Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients[8] - (Full text)
  • 2015, Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients][9] - (Abstract) - small study - 115 people with ME/CFS
  • 2015, Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis[10] - [https://onlinelibrary.wiley.com/doi/10.1111/sji.12388/abstract (Abstract)

News and blogs[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (14). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  2. Cabanas, Helene; Muraki, Katsuhiko; Eaton-Fitch, Natalie; Staines, Donald Ross; Marshall-Gradisnik, Sonya (2021). "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment". Frontiers in Immunology. 12: 687806. doi:10.3389/fimmu.2021.687806. ISSN 1664-3224. PMC 8313851. PMID 34326841.
  3. Cabanas, Helene; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (October 14, 2019). "Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients". Frontiers in Immunology. doi:10.3389/fimmu.2019.02545.
  4. Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in Natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (2). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551. PMC 6092868. PMID 30134818.
  5. Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  6. Marshall-Gradisnik, S.M.; Chacko, A.; Johnston, S.; Smith, P.; Nilius, B.; Staines, D.R. (January 1, 2016). "Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients". Immunology and Immunogenetics Insights. 8: III.S37042. doi:10.4137/III.S37042. ISSN 1178-6345.
  7. Huth, Teilah Kathryn; Staines, Donald; Marshall-Gradisnik, Sonya (April 21, 2016). "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Journal of Translational Medicine. 14 (1): 97. doi:10.1186/s12967-016-0859-z. ISSN 1479-5876. PMC 4839077. PMID 27098723.
  8. Nguyen, T.; Staines, D.; Nilius, B.; Smith, P.; Marshall-Gradisnik, S. (May 31, 2016). "Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients". Biological Research. 49 (1): 27. doi:10.1186/s40659-016-0087-2. ISSN 0717-6287. PMC 4888729. PMID 27245705.
  9. Marshall-Gradisnik, Sonya M.; Smith, Peter; Brenu, Ekua W.; Nilius, Bernd; Ramos, Sandra B.; Staines, Donald R. (January 1, 2015). "Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients". Immunology and Immunogenetics Insights. 7: III.S25147. doi:10.4137/III.S25147. ISSN 1178-6345.
  10. Huth, T.K.; Brenu, E.W.; Ramos, S.; Nguyen, T.; Broadley, S.; Staines, D.; Marshall‐Gradisnik, S. (2016). "Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis". Scandinavian Journal of Immunology. 83 (1): 44–51. doi:10.1111/sji.12388. ISSN 1365-3083.